Breaking News Instant updates and real-time market news.

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07

Barron's suggests dividend stocks for retirement savers

In this week's Barron's cover story, Lawrence Strauss wrote that "for investors who are saving for retirement, dividend stocks are a crucial building block." He noted that Columbia Dividend Income fund has had success with a total-return strategy, with a 10-year annual return of 12.2%, had top holdings including JPMorgan Chase (JPM), Microsoft (MSFT), Johnson & Johnson (JNJ), and Merck (MRK). For those not interested in a fund, Buckingham suggested dividend stock it believed were undervalued -- Royal Caribbean Cruises (RCL), Cisco Systems (CSCO), Amgen (AMGN), AT&T (T), KeyCorp (KEY), Synchrony Financial (SYF), and Prudential Financial (PRU). Also suggested was the Vanguard Dividend Growth fund, with its top holdings in "high-quality and defensive companies," including Coca-Cola (KO), Medtronic (MDT), and McDonald's (MCD). Reference Link

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 22

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

MCD McDonald's
$193.95

-0.02 (-0.01%)

11/08/19
11/08/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) upgraded to Buy from Neutral at Longbow with analyst Alton Stump saying though disappointed by Steve Easterbrook's departure, Chris Kempczinski has played an integral role alongside Easterbrook in driving the company's "impressive" domestic same-store sales recovery and he believes McDonald's "is in good hands" under its new CEO. 2. Foot Locker (FL) upgraded to Positive from Neutral at Susquehanna with analyst Sam Poser saying he believes its outlook for Q3 and Q4 will be better than anticipated. 3. WWE (WWE) upgraded to Buy from Neutral at Citi with analyst Jason Bazinet saying the stock's risk/reward is "now compelling." 4. Qualcomm (QCOM) upgraded to Hold from Sell at DZ Bank. 5. Cummins (CMI) upgraded to Outperform from In Line at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/08/19
LBOW
11/08/19
UPGRADE
Target $227
LBOW
Buy
Longbow says McDonald's 'in good hands,' upgrades to Buy after selloff
As previously reported, Longbow analyst Alton Stump upgraded McDonald's to Buy from Neutral with a $227 price target. Though disappointed by Steve Easterbrook's departure, Stump said Chris Kempczinski has played an integral role alongside Easterbrook in driving the company's "impressive" domestic same-store sales recovery and he believes McDonald's "is in good hands" under its new CEO. While the company will face more challenging same-store sales growth comparisons next year, his franchisee contacts are confident more locations offering delivery, recent and upcoming mobile technology improvements and additional remodels can drive 3.5%-4.0% same-store sales growth in 2020, the analyst added.
11/08/19
LBOW
11/08/19
UPGRADE
Target $227
LBOW
Buy
McDonald's upgraded to Buy from Neutral at Longbow
Longbow analyst Alton Stump upgraded McDonald's to Buy from Neutral with a $227 price target.
11/05/19
BERN
11/05/19
UPGRADE
Target $106
BERN
Outperform
Beyond Meat upgraded to Outperform from Market Perform at Bernstein
Bernstein analyst Alexia Howard upgraded Beyond Meat (BYND) to Outperform from Market Perform with an unchanged price target of $106. The stock closed Monday down 3% to $79.79. The analyst is making a "straightforward valuation call" with the shares down 66% from their peak. Howard says that while selling pressure is likely to persist in the near-term, her fair value estimate is based on multiples awarded to other high-growth consumer peers and suggests share downside is limited. She believes Beyond Meat should trade at eight to 10 times enterprise value to sales, implying a fair value range between $84 to $130. The key is whether the company can partner with McDonald's (MCD), who is currently doing trials of a Beyond Meat burger in Canada, Howard tells investors in a research note. Her channel checks suggest the trials are going well, "but not well enough to justify an immediate nationwide rollout." She assumes a 50% probability of one materializing.
MDT Medtronic
$112.11

2.9 (2.66%)

11/01/19
PIPR
11/01/19
INITIATION
Target $39
PIPR
Overweight
Axonics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Adam Maeder initiated coverage of Axonics Modulation Technologies (AXNX) with an Overweight rating and $39 price target. Although there is some investor disappointment that U.S. launch didn't commence sooner and urinary approval is still pending, Axonics remains positioned for commercial success and "strong" sales growth next year, Maeder tells investors in a research note. He believes the company's r-SNM has meaningful advantages over Medtronic's (MDT) InterStim II product and sees "plenty of room in the market for a second competitor."
09/25/19
GUGG
09/25/19
NO CHANGE
GUGG
Neutral
Medtronic financial projections for Hugo robot 'underwhelming,' says Guggenheim
After attending Medtronic's (MDT) "much-anticipated" robotic-assisted surgery event, where the company gave a first look at the Hugo RAS system, Guggenheim analyst Chris Pasquale noted that the company gave an update on regulatory timelines and initial revenue targets, though information on pricing and clinical comparability to Intuitive Surgical's (ISRG) da Vinci system were "notably absent." He was impressed by certain design elements, though he thinks management's financial projections for Hugo were "somewhat underwhelming," said Pasquale, who keeps a Neutral rating on Medtronic shares.
09/27/19
PIPR
09/27/19
NO CHANGE
PIPR
Piper says insulin pump survey most positive for Insulet
Piper Jaffray analyst JP McKim conducted an insulin delivery survey in August and found that pump penetration is going "much higher" both in type 1s and in type 2s. The growth in the type 2 market is underappreciated by investors and will largely benefit Insulet (PODD) today given the pharmacy channel increases that access, McKim tells investors in a research note. Further, survey indicated that Medtronic (MDT) is expected to lose between 1,100-1,300 basis points of market share with Tandem Diabetes (TNDM) being the greatest beneficiary with the biggest uptick forecast in 2020, says the analyst. McKim views the insulin pump survey as most positive for Insulet.
11/05/19
PIPR
11/05/19
NO CHANGE
PIPR
Overweight
Medtronic filed patent lawsuit against Axonics, says Piper Jaffray
Piper Jaffray analyst Adam Maeder says Medtronic (MDT) yesterday filed a lawsuit with the U.S. District Court for the Central District of California alleging that Axonics Modulation Technologies' rechargeable sacral neuromodulation system infringes its U.S. patents. As part of the lawsuit, Medtronic is seeking injunctive relief and damages for alleged intellectual property infringement, the analyst points out. The timing of the lawsuit coincides with Axonics' U.S. commercial launch, says Maeder, who points out that patent litigation is not uncommon in the medical device sector and generally takes a while to play out. He expects Axonics to "defend itself vigorously and continue to sell r-SNM throughout the ongoing legal process."
KO Coca-Cola
$52.67

0.03 (0.06%)

10/23/19
10/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Coca-Cola (KO) upgraded to Buy from Neutral at UBS with analyst Sean King saying the company is "effectively navigating" aggressive U.S. price increases, a transformational deal for Costa, and demonstrating strong innovation capabilities while reinvigorating growth in high-margin sparkling. 2. Biogen (BIIB) upgraded to Outperform from Market Perform at SVB Leerink and to Buy from Neutral at Guggenheim. 3. Snap (SNAP) upgraded to Overweight from Neutral at JPMorgan and to Hold from Underperform at Needham. 4. Travelers (TRV) upgraded to Hold from Sell at Deutsche Bank with analyst Joshua Shanker saying while management warned investors six weeks ago to expect headwinds from a challenging environment from tort severity, Travelers' Q3 results were still materially worse than expected. 5. PPL Corp. (PPL) upgraded to Neutral from Underperform at Macquarie with analyst Angie Storozynski saying an M&A deal is increasingly likely as it would solve the company's balance sheet and dividend problems. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/11/19
JEFF
11/11/19
NO CHANGE
Target $30
JEFF
Underperform
National Beverage estimates and price target lowered at Jefferies
Jefferies analyst Kevin Grundy lowered his estimates for National Beverage (FIZZ) saying Coca-Cola's (KO) new sparkling water brand "should be a wake-up call." Post PepsiCo's (PEP) successful launch of the bubly brand in 2018, Coca-Cola will be playing catch-up in the fast-growing sparkling water space with its first major brand launch since 2006, Grundy tells investors in a research note. He believes "bigger and bolder decisions" are called for at National Beverage, which he says has been slow to respond with its "once-leading" La Croix brand. Grundy lowered his price target for the shares to $30 from $32 and keeps an Underperform rating on National Beverage.
11/01/19
JEFF
11/01/19
NO CHANGE
JEFF
Sports and energy drinks still strong in Europe, says Jefferies
European Nielsen sales trends were little changed for the four weeks ended October, with sports/energy drinks and salty snacks "still strong" at up 5.7% and up 5.1%, respectively, Jefferies analyst Kevin Grundy tells investors in a research note. In addition, Monster Beverage (MNST) gained share despite the launch of Coke Energy (KO), the analyst adds. He notes that European carbonated soft drinks "remain muted" as the industry cycles difficult year-over-year comps. Monster and Coca-Cola European Partners (CCEP) remain Grundy favored cap beverage stocks.
10/23/19
MSCO
10/23/19
NO CHANGE
Target $125
MSCO
Overweight
Procter & Gamble results could bode well for Walmart, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman noted that three of the four companies with the greatest weight in the Consumer Staples Sector SPDR (XLP) - PepsiCo (PEP), Coca-Cola (KO) and now Procter & Gamble (PG) - have reported solid Q3 results. He thinks the group's momentum could have a positive read-through to Walmart (WMT), which will report its fiscal Q3 results on November 14. Gutman added that the correlation between Walmart's total comps and P&G volume growth on a trailing five year basis has improved in the past couple of quarters and both companies' revenue trajectories have trended in a similar direction since "around 2015." Gutman keeps an Overweight rating on Walmart shares with a $125 price target.
PRU Prudential
$93.61

0.82 (0.88%)

11/05/19
11/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Buy from Conviction Buy at Goldman Sachs and to Neutral from Outperform at Baird. 2. Hudson (HUD) downgraded to Underperform from Neutral at BofA/Merrill with analyst Marisa Sullivan saying after a "disappointing" set of Q3 results and Q4 guidance, she sees an "increasingly uncertain" outlook for the company's core business despite the contributions being made from the OHM and Brookstone acquisitions. 3. Stryker (SYK) downgraded to Equal Weight from Overweight at Barclays with analyst Kristen Stewart saying while Stryker remains a "strong company fundamentally," the stock's performance over the next year is likely to be restrained by the outstanding Wright Medical Group (WMGI)m which is not expected to close until Q3 of 2020. 4. U.S. Steel (X) downgraded to Hold from Buy at Argus with analyst David Coleman saying its Q3 earnings came in "significantly short" relative to his estimates. 5. Prudential (PRU) downgraded to Market Perform from Outperform at Wells Fargo with analyst Elyse Greenspan saying the company's quarterly EPS of $3.22 handily beat estimates, but this was the second quarter in a row where earnings have been re-based lower. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/05/19
KBWI
11/05/19
DOWNGRADE
Target $102
KBWI
Market Perform
Prudential downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Ryan Krueger downgraded Prudential to Market Perform from Outperform with a price target of $102, down from $107. To reflect softer business growth and lower individual annuity margins, the analyst further reduced his estimates for Prudential. He now forecasts an intermediate-term return on equity towards the low-end of the company's 12%-14% target and more in-line with peers. Prudential's interest rate sensitivity is greater than anticipated, says Krueger, who does not expect the company's cost save actions to meaningfully contribute until 2022.
11/05/19
WELS
11/05/19
DOWNGRADE
Target $92
WELS
Market Perform
Prudential downgraded to Market Perform at Wells Fargo, price target cut to $92
Wells Fargo analyst Elyse Greenspan downgraded Prudential to Market Perform from Outperform with a price target of $92, down from $105. In a research note to investors, Greenspan notes that the company's quarterly EPS of $3.22 handily beat estimates, but notes that this was the second quarter in a row where earnings have been re-based lower. Greenspan says she is using this as an opportunity to move to the sidelines. While Prudential has been working on its financial wellness initiatives, which should improve its margin and return prospects, the analyst states that the positive impact of these initiatives will not start to be felt in numbers until late next year.
11/06/19
11/06/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Groupon (GRPN) downgraded to Underweight from Neutral at JPMorgan with analyst Doug Anmuth saying while he is encouraged by the company's efforts toward improving customer conversion, he thinks those efforts will take time to offset traffic and international macro headwinds. 2. Altice USA (ATUS) downgraded to Sector Weight from Overweight at KeyBanc and to Equal Weight from Overweight at Barclays. 3. Prudential (PRU) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Ryan Krueger saying to reflect softer business growth and lower individual annuity margins, he further reduced his estimates for Prudential. 4. KeyCorp (KEY) downgraded to Neutral from Outperform at Baird with analyst David George saying shares have reached his price target and although he is comfortable with the company outlook, he would wait for a better entry point for the shares. George maintained his $19 price target on KeyCorp shares. 5. WW (WW) downgraded to Neutral from Buy at DA Davidson with analyst Linda Weiser saying subscribers exceeded her estimate in the quarter, but that did not translate to gross margin upside, which is concerning given the dampening effect on sales of the studio to digital shift. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SYF Synchrony
$37.05

0.34 (0.93%)

08/16/19
DBAB
08/16/19
DOWNGRADE
Target $158
DBAB
Hold
Deutsche Bank downgrades Alliance Data on 'multiple potential headwinds'
Deutsche Bank analyst Ashish Sabadra downgraded Alliance Data Systems (ADS) to Hold from Buy and lowered his price target for the shares to $158 from $162. The analyst sees "multiple potential headwinds" for the company, including the reserve build, winding down portfolio held for sale, and declining interest rates weighing on earnings growth in 2020. The analyst points out that his 2020 earnings estimates are 10% below consensus. Alliance Data could continue to trade at a discount to Synchrony Financial (SYF) given its use of non-GAAP earnings and limited disclosures about consumer credit scores and revenue share, Sabadra tells investors in a research note.
09/24/19
MSCO
09/24/19
NO CHANGE
MSCO
Large-cap banks aren't gaining deposit market share, says Morgan Stanley
Morgan Stanley analyst Ken Zerbe said he continues to hear the "false narrative" that large-cap banks must be gaining market share due to their superior technology, but he insists they are not and that small and mid-cap banks have consistently gained deposit market share over the last five years. Individual large-cap banks that have had the biggest deposit share gains include Goldman Sachs (GS), Ally Financial (ALLY) and Synchrony Financial (SYF), while mid-cap banks that have delivered the biggest gains in share of total deposits include First Republic (FRC), KeyCorp (KEY) and Huntington (HBAN), Zerbe tells investors. Large-cap banks that have seen the largest declines in their respective individual shares of total deposits include JPMorgan (JPM), Wells Fargo (WFC) and Citigroup (C), while deposit share losers among mid-cap banks include Comerica (CMA), Prosperity Bancshares (PB) and Zions (ZION), said Zerbe.
09/11/19
NOMU
09/11/19
NO CHANGE
Target $43
NOMU
Buy
Synchrony price target raised to $43 from $39 at Nomura Instinet
Nomura Instinet analyst Bill Carcache raised his price target for Synchrony Financial to $43 from $39 saying his bullish outlook was reaffirmed in recent meetings with management. The analyst expects Synchrony to continue its upward trajectory through the rest of this year. He keeps a Buy rating on the shares.
08/20/19
RHCO
08/20/19
NO CHANGE
Target $160
RHCO
Buy
Alliance Data price target lowered to $160 from $180 at SunTrust
SunTrust analyst Andrew Jeffrey lowered his price target on Alliance Data (ADS) to $160 citing the risks around its uncertain portfolio composition from "repositioning of the book", rising credit costs in a recession, dilution from the potential Loyalty segment sale, and increased competition. The analyst is keeping his Buy rating on the Alliance Data stock however, saying its valuation is still at a 20% discount relative to its closest competitor Synchrony (SYF) which creates an "attractive" risk-reward.
KEY KeyCorp
$18.96

0.1 (0.53%)

10/25/19
DBAB
10/25/19
DOWNGRADE
Target $19
DBAB
Hold
KeyCorp downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded KeyCorp to Hold from Buy with a $19 price target.
11/06/19
BARD
11/06/19
DOWNGRADE
Target $19
BARD
Neutral
KeyCorp downgraded to Neutral at Baird
Baird analyst David George downgraded KeyCorp to Neutral from Outperform following its recent share price move. The analyst said shares have reached his price target and although he is comfortable with the company outlook, he would wait for a better entry point for the shares. George maintained his $19 price target on KeyCorp shares.
11/06/19
BARD
11/06/19
DOWNGRADE
Target $19
BARD
Neutral
KeyCorp downgraded to Neutral from Outperform at Baird
Baird analyst David George downgraded KeyCorp to Neutral from Outperform with a $19 price target.
T AT&T
$39.49

0.53 (1.36%)

11/14/19
11/14/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Sell from Hold at Maxim with analyst Nehal Chokshi saying his survey data lead him to project iPhone revenue in fiscal Q2 that is 14% below consensus iPhone revenue that is 6% below consensus for fiscal year 2020. He also expects operating profit to decline year-over-year due to his below consensus iPhone view. 2. Kraft Heinz (KHC) downgraded to Sell from Neutral at Goldman Sachs with analyst Jason English saying shares are up 15% since the company reported Q3 results on October 31. 3. Verizon (VZ), AT&T (T), and T-Mobile (TMUS) downgraded to Hold from Buy at HSBC. 4. Myomo (MYO) downgraded to Neutral from Buy at Roth Capital with analyst Scott Henry saying he sees lowered future expectations for the company after its Q3 results missed expectations. 5. Albemarle (ALB) downgraded to Neutral from Buy at Seaport Global with analyst Michael Harrison saying "challenging" lithium market dynamics are now anticipated to continue though 2020. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/06/19
GUGG
11/06/19
DOWNGRADE
Target $10
GUGG
Sell
Guggenheim downgrades CenturyLink to Sell with unchanged $10 target
Guggenheim analyst Mike McCormack downgraded CenturyLink (CTL) to Sell from Neutral with an unchanged price target of $10. The stock closed Tuesday up 2c to $13.67. The shares are up 41% since late May and industry data points are not encouraging, McCormack tells investors in a research note. The analyst says both comments and results from AT&T (T) and Verizon Communications (VZ) reaffirm his negative stance on the macro environment and developing trends in Wireline. Wireline results at AT&T and Verizon showed significant weakness, McCormack points out. Margin pressures for both in Wireline cause "significant concern for pure-play" CenturyLink, adds the analyst. Further, McCormack continues to believe that CenturyLink management is not likely wedded to the dividend. He has a hard time believing that the over $1B annual payment wouldn't be more appropriately applied to the company's nearly $35B of debt.
11/14/19
HSBC
11/14/19
DOWNGRADE
Target $42
HSBC
Hold
AT&T downgraded to Hold from Buy at HSBC
HSBC analyst Sunil Rajgopal downgraded AT&T to Hold from Buy with a $42 price target.
11/14/19
HSBC
11/14/19
DOWNGRADE
HSBC
HSBC downgrades AT&T, Verizon, T-Mobile and Altice USA to Hold
HSBC analyst Sunil Rajgopal downgraded to Hold from Buy shares of AT&T (T), Verizon Communications (VZ), T-Mobile (TMUS) and Altice USA (ATUS). The analyst's only Buy in US Telecoms is now Comcast (CMCSA). Rajgopal keeps Reduce ratings on both Dish (DISH) and Sprint (S). The "evolving content business model" and increasing competition leads the analyst to be more cautious on the pay-TV business and operators with greater exposure to content revenues. Producers are increasingly distributing their content directly to consumers rather than relying on the cable and satellite aggregators, Rajgopal tells investors in a research note. In addition, the entry of a "well-funded" companies like Apple (AAPL) into content production and distribution "with its low sticker price adds to the concerns," contends the analyst. Rajgopal cut his pay-TV subscriber estimates for Comcast, AT&T, Charter and Altice USA to reflect his more cautious stance. The analyst lowered his price target for Altice USA to $28 from $30, raised his price target for AT&T to $42 from $38, raised his price target for Verizon to $65 from $62, and kept an $86 price target on T-Mobile.
AMGN Amgen
$220.84

2.29 (1.05%)

11/12/19
RHCO
11/12/19
INITIATION
Target $256
RHCO
Buy
Amgen initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of Amgen with a Buy rating and $256 price target. The analyst expects the company's growth rate to recover thanks to its biosimilars business, its ability to develop mid-cycle products, and its interest in the Chinese drug market.
11/13/19
COWN
11/13/19
NO CHANGE
Target $225
COWN
Outperform
BeiGene price target raised to $225 from $170 at Cowen
Cowen analyst Yaron Werber raised his price target on BeiGene (BGNE) to $225 from $170 following Q3 results. the report was light due to supply issues for Abraxane, which should reverse in Q4. The analyst said the recent deal with Amgen (AMGN) removes any financing needs, provides a steady pipeline, and provides for 3 new launches in China in 2020 and 2021. Werber reiterated his Outperform rating on BeiGene shares.
11/05/19
11/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Outperform at Daiwa with analyst Satoshi Tanaka saying the company's Q3 results and 2020 outlook last week go a "long way to alleviate concerns." 2. Beyond Meat (BYND) upgraded to Outperform from Market Perform at Bernstein with analyst Alexia Howard saying she is making a "straightforward valuation call" with the shares down 66% from their peak. 3. NXP Semiconductors (NXPI) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying the company's auto segment is showing signs of recovery, with easier compares and content wins. 4. Amgen (AMGN) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Alethia Young saying recent events have set the stage for a "clean base business and pipeline story" for Amgen in 2020. 5. Autoliv (ALV) upgraded to Buy from Neutral at Mizuho with analyst Vijay Rakesh saying an improving 2020-2021 auto outlook with easier compares, continued airbag market share gains versus Takata, and lower product launch costs position Autoliv well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/19
11/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arlo Technologies (ARLO) resumed with a Buy at Deutsche Bank. 2. Clarivate Analytics (CCC) initiated with a Hold at Stifel. 3. Stoke Therapeutics (STOK) initiated with a Buy at BTIG. 4. BioMarin (BMRN), Biogen (BIIB), and Amgen (AMGN) were initiated with a Buy at SunTrust. 5. Corteva (CTVA) initiated with a Buy at Redburn. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CSCO Cisco
$45.10

0.18 (0.40%)

11/14/19
COWN
11/14/19
NO CHANGE
Target $59
COWN
Outperform
Cisco growth will return with macro recovery, says Cowen
Cowen analyst Jim Suva reduced his estimates on Cisco following its Q3 results as he believes the breadth of its weak results supports the view that the outlook is macro driven. The analyst said weak environment and margin trajectory suggests that earnings power will meaningfully improve when growth returns with the eventual macro recovery. Suva reiterated his Outperform rating and lowered his price target to $59 from $61 on Cisco shares.
11/14/19
OPCO
11/14/19
NO CHANGE
Target $55
OPCO
Outperform
Cisco price target lowered to $55 from $57 at Oppenheimer
Oppenheimer analyst Ittai Kidron lowered his price target for Cisco to $55 from $57 after the company reported "solid" October-quarter results but offered weak guidance for the January quarter. Kidron tells investors in a research note that the bad news is that the negative revisions reflect ongoing weakness in emerging markets and SPs as well as new softness in the important enterprises and commercial verticals, but says the good news is that estimates have likely been appropriately reset to reflect continued softness, operating margins continue to impress, and product mix continues to improve with more software/subscription. Kidron, who maintains an Outperform rating, says shares are likely to remain under pressure in the near-term, but thinks estimates have been substantially de-risked and with a solid capital program, downside is limited.
11/14/19
JEFF
11/14/19
NO CHANGE
Target $52
JEFF
Buy
Cisco valuation and dividend should protect downside, says Jefferies
Jefferies analyst George Notter says he's keeping a Buy rating on Cisco Systems despite last night's weaker sales guidance and incremental macro uncertainty. He expects the company will preserve earnings power as margins expand and cost cuts get implemented. Further, "below-market" valuations and the dividend yield should also help protect downside in the stock, says Notter, who lowered his price target for the shares to $52 from $54.
11/14/19
BARD
11/14/19
NO CHANGE
Target $52
BARD
Outperform
Cisco weakness from China and macro challenges, says Baird
Baird analyst Jonathan Ruykhaver said Cisco posted its second consecutive disappointing quarterly results and its guidance is also below expectations. The analyst said macro challenges continue to weigh on the company's outlook as well as the outlook in China and new weakness in commercial and enterprise segments. He did note that security was a bright spot in the quarter. Ruykhaver maintained his Outperform rating and lowered his price target to $52 from $54 on Cisco shares.
RCL Royal Caribbean
$117.91

2.69 (2.33%)

10/14/19
JPMS
10/14/19
NO CHANGE
Target $138
JPMS
Overweight
JPMorgan positive on Royal Caribbean, Norwegian into Q3 reports
JPMorgan analyst Brandt Montour is positive on shares of Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH) into the Q3 earnings reports. "Reasonably good" results and outlooks against a backdrop of "muted" expectations, poor sentiment and valuations near multi-year lows, will be enough to move the stocks higher, Montour tells investors in a research note. He expects both companies to report "solid" Q3 results, keep 2019 EPS guidance intact, and generally sound upbeat regarding 2020 bookings. Montour keeps an Overweight rating on both Royal and Norwegian, with reduced price targets of $138 and $59, respectively.
10/04/19
MSCO
10/04/19
NO CHANGE
MSCO
Royal Caribbean, Norwegian still sounding upbeat, says Morgan Stanley
Morgan Stanley analyst Jamie Rollo said following his meetings with senior management of Carnival (CCL), Norwegian Cruise Line (NCLH) and Royal Caribbean (RCL) that the management teams of both of the latter two cruise line operators expressed surprise at the weak outlook cited by Carnival last week. Apart from a short-term impact from hurricane Dorian, neither Royal nor Norwegian said they have seen a demand slowdown and Norwegian additionally said it has not seen a softening of its onboard revenue, which it considers to be the best real time indicator of consumer health, reported Rollo, who said both of the companies "still sound upbeat." Rollo has Equal Weight ratings on Carnival and Royal Caribbean and an Overweight rating on shares of Norwegian.
09/23/19
NOMU
09/23/19
NO CHANGE
NOMU
Nomura says Royal Caribbean, Norwegian weakness overdone on Thomas Cook news
Nomura Instinet analyst Harry Curtis notes that cruise stocks are lower today following the bankruptcy filing by Thomas Cook, which he believes is due to fears about the industry's financial exposure to the U.K. firm. However, the industry's exposure is "insignificant" as cruise bookings for Thomas Cook are "miniscule" relative to the firm's air and hotel businesses, said Curtis. Royal Caribbean (RCL) booked only 20,000-25,000 passengers per year through Q3 and Norwegian Cruise Line's (NCLH) exposure is even smaller, at roughly 2,000 bookings, according to Curtis, who said both were paid in cash at or before sailing. The analyst recommends using today's pullback as an opportunity to accumulate shares of those two cruise line operators. In afternoon trading, Royal Caribbean shares are down 2%, Norwegian shares are down 1% and industry peer Carnival (CCL) has fallen 2%.
10/18/19
MACQ
10/18/19
UPGRADE
Target $132
MACQ
Outperform
Royal Caribbean upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Paul Golding upgraded Royal Caribbean to Outperform from Neutral with a price target of $132, up from $126. At the "current near-trough" price-to-earnings multiple, Royal Caribbean shares offer "substantially more upside than downside," Golding tells investors in a research note. While near-term results could be "messy," Hurricane Dorian is a one-time event, and booking sentiment remains strong aside from Dorian, says the analyst.
MRK Merck
$84.89

0.33 (0.39%)

11/08/19
LEER
11/08/19
NO CHANGE
LEER
Outperform
Merck data a 'much needed positive' for Aduro Biotech, says SVB Leerink
SVB Leerink analyst Daina Graybosch noted that Merck (MRK) presented data in a late-breaking oral session at the SITC meeting on the dose escalation and confirmation phases of its trial of MK-5890, which is licensed from Aduro Biotech (ADRO). The "surprisingly positive" signal in dose escalation, while very early, should not have much stock impact for Merck, but for Aduro "this is some much needed positive news," according to Graybosch. She has an Outperform rating on Aduro shares.
10/30/19
MZHO
10/30/19
NO CHANGE
Target $100
MZHO
Buy
Merck price target raised to $100 from $97 at Mizuho
Mizuho analyst Mara Goldstein raised her price target for Merck to $100 from $97 saying the company delivered a "strong" Q3 earnings beat and raised fiscal 2019 sales and EPS guidance. The analyst continues to see opportunity for Keytruda to drive a profit transformation over the next several years and reiterates a Buy rating on the shares.
10/17/19
BOFA
10/17/19
NO CHANGE
BOFA
Vertex added to US 1 List, Merck, Ferrari removed at BofA/Merrill
10/18/19
MZHO
10/18/19
NO CHANGE
Target $97
MZHO
Buy
Merck's Keytruda pulling farther ahead of competition, says Mizuho
Mizuho analyst Mara Goldstein reiterated her Buy rating and $97 price target on Merck shares after the announcement of positive EU CHMP opinions for Keytruda monotherapy and in combination with chemotherapy for first-line head and neck squamous cell carcinoma, or HNSCC. She sees Keytruda pulling farther ahead of its competition as the leading checkpoint inhibitor as it continues to penetrate additional tumor types and global markets, Goldstein tells investors.
JNJ Johnson & Johnson
$134.97

3.99 (3.05%)

10/30/19
MSCO
10/30/19
NO CHANGE
MSCO
Morgan Stanley says J&J talc test 'not an all clear,' but incremental positive
Morgan Stanley analyst David Lewis noted that Johnson & Johnson announced that its independent testing concluded no presence of asbestos in the company's previously recalled baby powder, though the FDA subsequently stated, "They would say the product is free of asbestos based on their testing, and we would say the opposite for that sample." Though the FDA is standing behind its test, Lewis doesn't think this suggests a contentious disagreement, but rather a statement of fact for respective testing. The analyst, who said that he has more work to do to understand the results and protocols, said this news is "not an all clear," but it is an incremental positive.
10/16/19
10/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Underweight at Atlantic Equities. 2. FMC Corporation (FMC) upgraded to Outperform from Neutral at Baird with analyst Ben Kallo saying he believes FMC's new product introductions, expected share gains in key markets, and operating leverage can drive revenue and adjusted EBITDA growth in 2020 and beyond. 3. Pure Storage (PSTG) upgraded to Outperform from Market Perform at Raymond James with analyst Simon Leopold saying recent VAR/Distributor checks have reflected positive sentiment suggesting Pure can exceed current Street estimates and he has gained a greater appreciation for the market expansion offered by the new FlashArray//C. 4. PDF Solutions (PDFS) upgraded to Buy from Hold at Craig-Hallum with analyst Christian Schwab saying PDF Solutions is transitioning the company to an analytics software model, and believes that looking out 3-5 years, and in line with management's long term model shared at the company's Analyst Day, it can become a "Rule of 40" SaaS like company with 70% gross margins and in aggregate a 20% top line growth rate and 20% operating margin. 5. Builders FirstSource (BLDR) and BMC Stock Holdings (BMCH) upgraded to Overweight from Equal Weight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/19
FBCO
10/24/19
NO CHANGE
Target $163
FBCO
Outperform
Johnson & Johnson price target raised to $163 from $158 at Credit Suisse
Credit Suisse analyst Matt Miksic raised his price target for Johnson & Johnson to $163 from $158as he believes the agreement in principal on opioids reduces uncertainty. While the settlement announcement does not completely eliminate the litigation overhang for the company, it does ratchet down the uncertainty, and may potentially help investors begin to price in a narrower range of potential liability for Johnson & Johnson. In terms of fundamentals, the company's Q3 results and a steady cadence of new products and favorable pipeline updates has helped reinforce the strength and breadth of its growth drivers, he contends. Miksic reiterates an Outperform rating on the shares.
10/18/19
FBCO
10/18/19
NO CHANGE
Target $158
FBCO
Outperform
Credit Suisse says J&J 'unwelcome surprise' recall may also have positive signal
Credit Suisse analyst Matt Miksic said Johnson & Johnson's voluntary recall of a single lot of its baby powder was an "unwelcome surprise" for investors. However, despite the opportunity to take wider action, as the company did with Tylenol in 1982, J&J has chosen at this point to stand by its assertion that the baby powder does not contain asbestos, noted Miksic. On a related call, the company said the test results for the sample which triggered the recall are inconsistent with historical testing of the U.S. mine from which the lot was produced, which it said had been confirmed by third-party validation. Miksic, who continues to expect increasing clarity and reduced uncertainty around the range of potential liabilities facing the company, reiterated his Outperform rating and $158 price target on J&J shares.
MSFT Microsoft
$149.95

1.89 (1.28%)

11/07/19
MZHO
11/07/19
NO CHANGE
Target $20
MZHO
Neutral
Slack Technologies price target lowered to $20 from $24 at Mizuho
Mizuho analyst Gregg Moskowitz lowered his price target for Slack Technologies (WORK) to $20 from $24 and keeps a Neutral rating on the shares. The analyst says that while he continues to view Slack's communications/collaboration platform as "best-in-class," he's observed "strong fundamental progress" of Microsoft Teams (MSFT) over the past 12 months. Despite a material recent selloff in Slack shares, Moskowitz has an increased level of concern with respect to Microsoft Teams as a competitive threat to the company going forward following Microsoft's Ignite conference. He keeps a Neutral rating on Slack Technologies.
11/05/19
RSBL
11/05/19
UPGRADE
Target $13
RSBL
Buy
Applied Optoelectronics upgraded to Buy ahead of guidance at Rosenblatt
As previously reported, Rosenblatt analyst Jun Zhang upgraded Applied Optoelectronics (AAOI) to Buy from Neutral with a price target of $13, up from $10. When the company reports Q3 results tomorrow, Zhang believes it will provide guidance for sequential revenue growth in Q4, powered by Microsoft's (MSFT) increasing demand for 100G products and demand from Amazon (AMZN) for 40G products. In addition to demand in the U.S. hyperscale market, Zhang sees Applied benefiting in 2020 from potential opportunities in 5G, a likely design wins at ZTE (ZTCOY), and potential opportunities to supply to Cisco (CSCO) clients.
11/01/19
NEED
11/01/19
DOWNGRADE
NEED
Hold
Arista Networks downgraded to Hold from Buy at Needham
Needham analyst Alex Henderson downgraded Arista Networks (ANET) to Hold from Buy after its "weak" Q4 guidance, saying this marks the 3rd consecutive quarter of a cut in outlook. The analyst notes that while the prior delay in orders from Microsoft (MSFT) has now come back, another larger customer - "most likely" Facebook (FB) - has sharply reduced its orders from Arista over the span of multiple quarters. Henderson adds that the reduction in outlook, along with the "unpredictability" of cloud demand, are likely to hurt valuations even when demand recovers.
11/01/19
BOFA
11/01/19
DOWNGRADE
Target $245
BOFA
Neutral
Arista Networks downgraded to Neutral from Buy at BofA/Merrill
BofA Merrill Lynch analyst Tal Liani downgraded Arista Networks (ANET) to Neutral from Buy after the company significantly reduced expectations for Q4 and said it no longer expects 2020 growth of 13-15% due to a "cloud titan" delaying network spending and expected delays in the 400G cycle ramping. Arista management said that the unnamed "cloud titan" customer is not Microsoft (MSFT), noted Liani. Though on the positive side he doesn't see any change in the competitive landscape and expects trends to improve with new products ramping and the 400G cycle, Liani has cut his estimates for Arista and lowered his price target on the stock to $245 from $360.
JPM JPMorgan
$129.51

0.83 (0.65%)

11/01/19
11/01/19
NO CHANGE

Rice University-Jones Graduate School of Business to hold a summit
Rice Energy Finance Summit will be held in Houston on November 1.
10/16/19
BMOC
10/16/19
NO CHANGE
Target $126
BMOC
Market Perform
JPMorgan price target raised to $126 from $120 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on JPMorgan to $126 after its Q3 earnings beat, driven by its higher than expected fees and lower costs. The analyst also raises his FY19 and FY20 EPS views by 21c and 9c to $10.73 and $11.13 respectively but keeps his Marker Perform rating on valuation, noting that its 2-year forward price-to-earnings multiple is just slightly below its long-term historical average.
10/16/19
RBCM
10/16/19
NO CHANGE
Target $125
RBCM
Outperform
JPMorgan price target raised to $125 from $120 at RBC Capital
RBC Capital analyst Gerard Cassidy raised his price target on JPMorgan to $125 and kept his Outperform rating after its Q3 earnings beat driven by "strong" fixed income/currency/commodity trading business and mortgage banking results. The analyst expects JPMorgan to continue its "successful" execution, overcoming any drag related to lower interest rate spread income. Cassidy also raises his FY19 and FY20 EPS views by 19c and 36c to $10.30 and $10.85, anticipating 1-2 more interest rate cuts next year followed by the steepening in the yield curve.
10/29/19
SOCG
10/29/19
DOWNGRADE
SOCG
Sell
JPMorgan downgraded to Sell from Hold at Societe Generale
Societe Generale analyst Andrew Lim downgraded JPMorgan to Sell from Hold.

TODAY'S FREE FLY STORIES

EVFM

Evofem

$6.30

0.03 (0.48%)

07:19
12/11/19
12/11
07:19
12/11/19
07:19
Recommendations
Evofem analyst commentary  »

Evofem price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PB

Prosperity Bancshares

$70.40

-0.31 (-0.44%)

07:18
12/11/19
12/11
07:18
12/11/19
07:18
Downgrade
Prosperity Bancshares rating change  »

Prosperity Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CASY

Casey's General Stores

$158.77

-16.56 (-9.45%)

07:17
12/11/19
12/11
07:17
12/11/19
07:17
Recommendations
Casey's General Stores analyst commentary  »

Casey's General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAG

IAMGold

$3.40

-0.05 (-1.45%)

07:16
12/11/19
12/11
07:16
12/11/19
07:16
Hot Stocks
IAMGold increases interest in Nelligan project by 24% for C$2.35M »

Vanstar Mining Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$1,250.39

79.085 (6.75%)

07:16
12/11/19
12/11
07:16
12/11/19
07:16
Conference/Events
AutoZone management to meet with Morgan Stanley »

Group Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

PRQR

ProQR Therapeutics

$9.09

0.44 (5.09%)

07:13
12/11/19
12/11
07:13
12/11/19
07:13
Hot Stocks
ProQR Therapeutics doses first patient in Phase 1/2 Aurora trial of QR-1123 »

ProQR Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTAI

BioXcel Therapeutics

$6.08

-0.07 (-1.14%)

07:12
12/11/19
12/11
07:12
12/11/19
07:12
Hot Stocks
BioXcel Therapeutics to expand BXCL701 study into multiple advanced solid tumors »

BioXcel Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAA

Plains All American

$18.01

0.49 (2.80%)

07:12
12/11/19
12/11
07:12
12/11/19
07:12
Recommendations
Plains All American analyst commentary  »

Plains All American price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Feb

WSR

Whitestone REIT

$13.66

-0.1 (-0.73%)

07:11
12/11/19
12/11
07:11
12/11/19
07:11
Hot Stocks
Whitestone REIT acquires Las Colina Village, terms not disclosed »

Whitestone REIT acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFIN

American Finance Trust

$14.53

-0.15 (-1.02%)

07:10
12/11/19
12/11
07:10
12/11/19
07:10
Conference/Events
American Finance Trust management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AHCO

AdaptHealth

$10.09

0.19 (1.92%)

07:10
12/11/19
12/11
07:10
12/11/19
07:10
Initiation
AdaptHealth initiated  »

AdaptHealth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIE

Viela Bio

$28.00

2 (7.69%)

07:10
12/11/19
12/11
07:10
12/11/19
07:10
Hot Stocks
Viela Bio initiates Phase 2b trial of VIB4920 in Sjogren's syndrome »

Viela Bio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XCUR

Exicure

$2.99

0.115 (4.01%)

07:09
12/11/19
12/11
07:09
12/11/19
07:09
Hot Stocks
Exicure announces update from AST-008 trial, to enroll patients in Phase 2 study »

Exicure announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCRX

BioCryst

$2.86

0.26 (10.00%)

07:08
12/11/19
12/11
07:08
12/11/19
07:08
Hot Stocks
BioCryst submits NDA for oral, once daily berotralstat for HAE attacks »

BioCryst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTI

Proteostasis

$3.96

0.44 (12.50%)

07:08
12/11/19
12/11
07:08
12/11/19
07:08
Hot Stocks
Proteostasis begins trial of proprietary modulators in cystic fibrosis »

Proteostasis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JOBS

51job

$81.19

1.88 (2.37%)

07:07
12/11/19
12/11
07:07
12/11/19
07:07
Initiation
51job initiated  »

Morgan Stanley starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBRA

Sabra Health Care

$21.87

-0.3 (-1.35%)

07:07
12/11/19
12/11
07:07
12/11/19
07:07
Syndicate
Breaking Syndicate news story on Sabra Health Care »

Sabra Health Care files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLCE

Children's Place

$70.67

0.68 (0.97%)

07:07
12/11/19
12/11
07:07
12/11/19
07:07
Earnings
Children's Place lowers FY19 adj. EPS view $5.00-$5.20 from $5.40-$5.75 »

Consensus $5.62. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

UNFI

United Natural Foods

$9.88

0.19 (1.96%)

07:06
12/11/19
12/11
07:06
12/11/19
07:06
Hot Stocks
United Natural Foods reports Q1 gross margin 12.81% of net sales »

Gross margin for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

AZO

AutoZone

$1,250.39

79.085 (6.75%)

07:05
12/11/19
12/11
07:05
12/11/19
07:05
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

CORV

Correvio

$1.39

(0.00%)

07:05
12/11/19
12/11
07:05
12/11/19
07:05
Downgrade
Correvio rating change  »

Correvio downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

JBLU

JetBlue

$18.89

-0.03 (-0.16%)

07:04
12/11/19
12/11
07:04
12/11/19
07:04
Hot Stocks
JetBlue reports November traffic up 3.7% »

JetBlue reported its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNFI

United Natural Foods

$9.88

0.19 (1.96%)

07:04
12/11/19
12/11
07:04
12/11/19
07:04
Hot Stocks
United Natural Foods CEO says 'we remain confident that UNFI is well-positioned' »

"We entered the new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

PLCE

Children's Place

$70.67

0.68 (0.97%)

07:04
12/11/19
12/11
07:04
12/11/19
07:04
Earnings
Children's Place sees Q4 adjusted EPS $1.48-$1.68, consensus $2.06 »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

UNFI

United Natural Foods

$9.88

0.19 (1.96%)

07:03
12/11/19
12/11
07:03
12/11/19
07:03
Hot Stocks
Breaking Hot Stocks news story on United Natural Foods »

United Natural Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.